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Purpose: Long-term treatment adherence for a chronic asymptomatic condition is a
demanding task for many patients. Treating progressive glaucoma can also be confounding
for physicians, particularly when management relies on assumption of adherence. This study
investigated associations between self-reported adherence and frequency of medication
changes due to glaucoma progression.
Methods: A total of 128 participants with primary open angle glaucoma were recruited from
glaucoma clinics in Flinders Eye Center, South Australia, and completed conﬁdential ques-
tionnaires. Information was obtained regarding beliefs about glaucoma and their treatment.
Adherence was assessed using the four-item Morisky, Green and Levine Medication
Adherence Questionnaire (MGL). Medical records were analyzed for the number of medica-
tion changes, due to glaucoma progression.
Results: Adherence to topical glaucoma medication was categorized as ‘high’ in 41.4%
(Morisky, Green and Levine (MGL). Data were analyzed for behaviors affecting adherence,
history of adherence, and reasons for changed adherence. Chi-squared test demonstrated
that there was no signiﬁcant association noted between adherence and changes in medica-
tion regime (χ2 (2,128)=0.968, P=0.915); however, a signiﬁcantly lower adherence was
detected if participants had difﬁculties with their drop regime (χ2 (2,128)=7.24, P=0.027)
or had help with drop insertion (χ2 (1,128)=9.77, P=0.008).
Conclusion: This study revealed a higher rate of non-adherence than has previously been
demonstrated in other studies. This may be attributed to the unique design of the conﬁdential
questionnaire and the independent and sympathetic questioning techniques used. Further
work to develop a speciﬁc glaucoma medication adherence questionnaire would be valuable
to enhance glaucoma management.
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Plain language summary
Glaucoma detection and management is a signiﬁcant chronic health care burden. In order to
ensure value from any treatment provided for individuals with glaucoma, it is important that
we evaluate patients’ adherence to prescribed medication and discuss how to optimize the
information received in a meaningful way. This study makes a valuable contribution to the
literature by demonstrating signiﬁcant levels of non-adherence with medication in a large
population of people with glaucoma. It also reveals that effective adherence monitoring
should be independent from the treating medics and that adherence monitoring should be a
vital part of glaucoma management. Consideration of these factors should be incorporated
into glaucoma patient treatment regimes.
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Introduction
TheWHO categorizes glaucoma as the second leading cause
of preventable blindness, with primary open-angle glaucoma
(POAG) accounting for the largest proportion.1 Glaucoma
prevalence is estimated to be 3% for people over 40 years,
increasing to 10% for people over 70 years.2 Glaucoma care
costs are currently estimated at $2.9 billion (US) and $144.2
million (Australia),2 and this is likely to increase as the
population ages in developed countries. As glaucoma care
costs increase with disease severity,3 preventing progression
is imperative to limit cost escalation.
Topical hypotensive therapy is the primary treatment
option, the aim of which is to reduce intra-ocular pressure
(IOP) to a “target” level. This “target” level varies depend-
ing on diagnosis and disease severity, but is aimed at
preventing further glaucomatous damage.4
Presently, there is no ﬁrm evidence to substantiate that
non-adherence to topical medication results in progression.5
This is largely due to the difﬁculties in measuring non-adher-
ence in glaucoma patients. It is well known that the treating
physicians’ ability to judge adherence is poor.6–9 Several
methods have been utilized in efforts to assess adherence in
patients, which have resulted in non-adherence ﬁgures for
topical glaucoma medication varying from 12% to 60%.10–20
Several studies have utilized electronic dosing aids to
measure adherence to topical medication. These dosing aids
are embedded with an electronic chip that records the time
and date the drop container is opened and closed. Cate et al11
compared an electronic adherence monitor with self-reported
adherence in a trial involving 208 participants. They found
that patients signiﬁcantly overestimated their adherence
compared to the electronic monitoring measurement. Chang
et al10 used a two-phase study to develop a predictive model
for non-adherence (n=122). They ﬁrst used an electronic
monitor to measure adherence over a 3-month period; the
second phase then used the same drop monitor and an alert
system in an attempt to improve adherence. They found that
black ethnicity, a lower self-reported adherence rate, and a
shorter duration of glaucoma treatment were all positive
indicators of non-adherence. The Travatan Dosing Aid
study (n=196)7 reported electronic dosing aid median adher-
ence to be 71%, notably lower than self-reported adherence
(95%). Adherence, which was assessed from 3 weeks after
the initial visit to 2 weeks before the follow-up visit, was
deﬁned as patients taking 75% of the prescribed daily dose.7
Electronic dosing aids, although considered to be the
gold standard of adherence measures, have their limitations.
They are expensive, can only be used over short periods, are
only available for certain medications, and as patients are
aware of monitoring, could result in increased adherence
compared to “typical” behavior. They also assume that
evidence of recorded doses is evidence of instillation.
Additionally, many of the studies using electronic dosing
aids only include participants on monotherapy (one type of
drop), which has been shown to have better adherence than
those prescribed additional medication.21,22 Furthermore,
Okeke et al7 reported a marked increase in adherence just
before clinic appointments. They also found that treating
doctors were unable to distinguish patients that were
deemed adherent with using their eyedrops (95% used)
from those that were deemed non-adherent (20% used).
These highlight the difﬁculties treating physicians face
with managing progressive glaucoma, especially when
patients demonstrate good IOP control.
Numerous studies have attempted to judge adherence
by looking at prescription reﬁlls and pharmacy records.
Medication possession ratio (MPR) is the amount of med-
ication a patient has (days’ supply) divided by the time
(number of days) between prescription reﬁlls. Insufﬁcient
medication over a period results in an MPR <1. The
Glaucoma Adherence and Persistence Study (GAPS)23 is
the largest retrospective study to measure adherence.
Pharmacy claims were analyzed for 13,977 subjects, and
a mean MPR of 0.64 was reported, over a follow-up period
of 22 months. However, the main limitation of using MPR
to determine adherence is that possession of medication is
not evidence of instillation. Also, if repeated prescriptions
are given with other medications, then patients may be
“stockpiling” rather than being adherent.
Questionnaires have been used extensively to investi-
gate self-reported non-adherence to medicines.11,12,14,23–27
Understanding the reasons behind non-adherence, and
addressing these issues, could be invaluable in improving
future adherence. However, since there is no available
standardized, validated questionnaire, speciﬁcally
designed to assess adherence to topical medication, com-
parison between studies is difﬁcult. In addition, physicians
involved in glaucoma care often conduct these
questionnaires, and patients are less likely to admit to
non-adherence in this situation.8 This study investigated
self-reported adherence in POAG by a researcher indepen-
dent of the care team. Uniquely, this study also assessed
the effect that changes in medication regimes have on
adherence.
McClelland et al Dovepress
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Methods
This study received ethical approval from Ulster
University Biomedical Sciences Ethics Filter Committee
and South Australia Health Human Research Ethics
Committee. All participants gave written informed consent
prior to involvement in the study.
Consecutive patients with POAG were recruited from
specialist glaucoma clinics within Flinders Eye Center
(South Australia) from May 2013 to May 2014. Eligible
participants had a conﬁrmed diagnosis of POAG and had
been using topical glaucoma medication for at least 3 years.
Participants were excluded if they had undergone previous
glaucoma surgery, were using topical medication for any
other eye condition, were over 85 years old, or unable to
read English. Participants were given a full explanation of the
study and written informed consent was obtained.
Participants were escorted to a quiet room to complete
the questionnaire in private. Once given the questionnaire,
it was reiterated that all responses were completely anon-
ymous and that their treating physician would have no
access to any information given to the researcher.
Participant records were later examined once the
patient had left the clinic and the numbers of medication
changes were recorded. Medication changes were only
included if the reason for change was due to evidence of
progression (ie, from IOP measurements, visual ﬁelds
progression, or Optical Coherence Tomography [OCT]
analysis). They were not included if the rationale for
change was due to side effects of eye drops or problems
with administration.
Questionnaire
To explore medication adherence in POAG, a customized
questionnaire was developed, which included questions
adapted from the Morisky, Green and Levine Medication
Adherence Questionnaire (MGL)28 and was based on analy-
sis of existing studies and questionnaire design speciﬁc to
POAG. TheMGL is an extensively used questionnaire which
has been validated for use with oral hypertensivemedications
and patients with Type 2 diabetes.28,29,30 Questions from the
MGL were used in the present study, comprising four ques-
tions with an option of a yes/no response. A “yes” was given
a score of 0 and a “no” 1. Therefore, total scores varied
between 0-4. The adherence scores were calculated, and
participants were categorized as: MGL=0-1 representing
low adherence, MGL=2-3 representing moderate adherence
and MGL=4 representing high adherence. Other questions
included in the questionnaire assessed patients’ knowledge
and beliefs about glaucoma, necessity of medication, and the
trust they had in their doctor and their treatment, as well as
factors that can predict non-adherence, based on previous
reports of glaucoma medication adherence.10–12,14,23,25,31,32
Questions also assessed patients’ use of eye drops, and their
routine and insertion techniques.
An independent researcher, a qualiﬁed optometrist not
involved with the participants’ treatment regime, adminis-
tered the questionnaire. Participants were allowed an open
dialogue and encouraged to volunteer as much information
as possible to make them feel more comfortable in admit-
ting non-adherence. Any participants who had speciﬁc
concerns that could not be answered by the researcher
were encouraged to discuss these with their glaucoma
physician.
Data were entered into SPSS version 21.0 and demo-
graphic and adherence behaviors were compiled. Analysis
of the medication change data found a non-normal distri-
bution, and median values were therefore reported.
Medication changes were therefore grouped into three
categories: group 1 (0 changes), group 2 (1 change), and
group 3 (2–4 changes). Non-parametric chi-squared ana-
lyses were employed to assess adherence and behaviors.
Results
Of the 138 participants recruited, ten were excluded for the
following reasons: four participants had previous trabecu-
lectomies, three had been on topical medication for less
than 3 years, one had experienced angle closure, and two
had their drops inserted by a carer in a nursing home.
Almost half of the participants were male (47.7%) and
the median age was 72.5 years (SD ±9.86). A large pro-
portion (71.1%) of participants had a family history of
glaucoma. The majority of participants in the study lived
with family (75.8%). A large proportion of the sample
(87.5%) was taking other chronic medications in addition
to their glaucoma eye drops. The median time since diag-
nosis of POAG was 9 years (SD ±5.89).
Adherence
For the remaining 128 participants, complete adherence to
topical medication was found in 41.4% (MGL=4).
‘Moderate adherence’ was demonstrated by 69 participants
(53.9%) and ‘low adherence’ by six participants (4.7%). The
reasons cited for non-adherence that participants mentioned
more than once are included in Table 1.
Dovepress McClelland et al
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Demographics and adherence
Table 2 summarizes the difference in participants cate-
gorised as having low, moderate or high adherence to
their medication. Older participants (over 70 years of
age) were more likely to demonstrate low adherence com-
pared with the younger individuals (χ2 (4,128)=10.62,
P=0.031). None of the parameters reached statistical sig-
niﬁcance (chi-squared, P>0.05) (Table 2).
History of adherence
The majority of participants (n=107, 83.6%) reported no
change in adherence behavior over the previous 6
months. A chi-squared test demonstrated that partici-
pants who reported no change in adherence behavior
were more likely to be in the ‘high adherence’ group
(χ2 (4,128)=15.89, P=0.03). Of the remaining 21 parti-
cipants, 12 reported that they used their medication
more regularly over the previous 6 months, and nine
less regularly. Table 3 summarizes the reasons given for
changes in adherence.
Knowledge of disease/patient perception
Less than half the participants (47.7%) felt they knew “a
lot/fair amount” about their glaucoma condition (Table 4).
A chi-squared test demonstrated no signiﬁcant associa-
tions between adherence and participants’ perception of
their knowledge of glaucoma when glaucoma knowledge
was categorized as knowing a ‘lot’, ‘a fair amount’, ‘very
little’ or ‘none’, χ2 (6,128)=2.56, P=0.862 (Table 4). Also,
no signiﬁcant associations were noted between participants
‘knowledge of glaucoma if left untreated’ and adherence
(χ2 (2,128)=3.84, P=0.146). Half of participants (50%)
reported they didn’t know or were unsure how the drops
for glaucoma worked, χ2 (2, 128)=7.89, P=0.096.
Less than a half (44.5%) of participants knew what
would happen if glaucoma was not treated.
Treatment of glaucoma
A large proportion of patients (66.4%) were very happy with
their treatment of glaucoma, the remainder were mostly
happy (29.7%), and a very small proportion (3.9%) unhappy.
Chi-squared test revealed that participants reporting that they
were “happy” with their treatment were more likely to be
adherent with their treatment, however this did not reach
statistical signiﬁcance, χ2 (2,128)=8.41, P=0.078) (Table 5).
When asked if they thought their eye drops were working,
half (50%) thought that their eye drops were working, almost
half (46.1%) replied that they were not sure, and the remain-
der (3.9%) responded “no”.
Use of eye drops
Most participants (89.1%) reported that they were conﬁdent
with their eye drop regime. The majority of participants used
their drops either once daily (54.7%) or twice daily (39.1%),
and 6.3% used them more than three times daily. Similarly,
most participants used either one (60.9%) or two types of
drops (33.6%), with 5.5% of participants using three types of
drops. Chi-squared test illustrated no signiﬁcant associations
between the frequency of drop regime and adherence (χ2 (3,
n=128)=2.47.46, P=0.872). The majority of participants
(82.8%) did not ﬁnd their drop regime “hard to follow”. Chi-
squared analysis indicated that participants with no difﬁculties
following with their drop regime had signiﬁcantly higher
adherence than those who reported difﬁculties, (χ2 (2,128)
=7.24, P=0.027) (Table 6). Eye drops stinging on insertion
was reported as “always” by 13.3% of participants and “some-
times” by 32.0%. Side effects using drops was reported by
24.2% of participants: the most common side effect reported
was red eyes (14.1%). There was no association found
between participants that reported “drops stung on insertion”
and their adherence (χ2 (4,128)=1.24 P=0.871).
The majority of participants reported that they were
“always” conﬁdent inserting their drops (73.4%), with
15.6% reporting conﬁdence with drop insertion “most of
the time”, 6.3% “occasionally”, and 4.7% “never”. Chi-
squared test revealed that over half the participants
(52.3%) had help with drop insertion at home if they
required it, and were more likely to be in the low-adherence
group (χ2 (1,128]=9.77, P=0.008). Just over a third (37.5%)
could recall being shown how to instill eye drops properly
Table 1 Participants’ reasons for not using eyedrops
Reason Frequency of
response, n (%)
Forget/bad memory 32 (25.0)
Change in routine 15 (11.7)
Traveling 7 (5.5)
Tiredness/late night 7 (5.5)
Ran out of drops 3 (2.3)
Lack of morning routine 2 (1.6)
Time of day – do not always use morning drops 2 (1.6)
Side effects: sore eyes 2 (1.6)
McClelland et al Dovepress
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or “could not remember” (39.9%), and the remainder
(22.7%) reported they had “never” been shown how to
instill drops properly. A large proportion (85.2%) of
participants had never asked for advice on drop instillation.
Discussion
It has previously been reported that physicians are not well
placed to accurately judge medication adherence6,7,9 and
that patients are unlikely to admit to non-adherence within
a clinic environment.8 Self-reported adherence is conven-
tionally disclosed as higher than other measures of adher-
ence, since social desirability compels patients to
overestimate adherence.
Interestingly, the adherence rate (41.4%) in this study
is one of the lowest reported rates using a questionnaire-
based study. Rees et al12 and Cate et al11 used the same
medication adherence and found a self-reported adherence
of 61.7% (n=107) and 87.8% (n=82), respectively; how-
ever, both the studies were conducted in a clinical envir-
onment. The present study demonstrates that segregating
participants from the clinic environment encourages non-
adherence disclosure.
While the MGL questions allowed a quick and easy
validated measure of adherence, its weakness is the inability
to measure the degree of non-adherence. 58.6% of partici-
pants scored either a ‘low adherence’ or ‘moderate adher-
ence’ score (MGL 0-3), with a signiﬁcant proportion in the
‘moderate adherence’ group. These two groups were not
quantiﬁed in terms of the number of times or regularity with
which they missed doses. The ‘moderately-adherent’
patients could be classed as non-intentional, ie, they simply
forgot, whereas the group of low adherence patients (scor-
ing 0-1 on the MGL [4.7% of total]) could indicate more
intentional non-adherence behaviors (eg, lack of faith in
treatment). These two differing patterns of behaviors need
altered approaches to management. Addressing the most
commonly reported reasons for non-adherence (eg, forget-
ting) may simply require patient counseling on the impor-
tance of drops, effects of missed drops, and ways to
improve future adherence. Patients that are intentionally
non-adherent may need a more diverse approach.
No signiﬁcant associations between adherence and the
number of changes in medication regime were found in this
study. There was a greater percentage of participants having
zero changes in medication’ in the ‘high adherence’ group,
however, only 21% of participants overall had two or more
glaucoma medication changes, thus limiting the conclusions
one can draw from this ﬁnding.
Table 2 Demographics compared with adherence rating with the MGL medication adherence questionnaire
Demographics Low
adherence
(MGL=0-1)
Moderate
adherence
(MGL=2-3)
High adherence
(MGL=4)
Chi-squared
P-value
Sex Male (n=61) 4.9% (n=3) 52.5% (n=32) 42.6% (n=26) χ2 (2,128)=0.1,
p=0.951Female (n=67) 4.5% (n=3) 55.2% (n=37) 40.2% (n=27)
Age ≤60 years (n=18) 16.6% (n=3) 61% (n=11) 22.2% (n=4) χ2 (4,128)=10.62,
p=0.031*61-70 years (n=38) 0% (n=0) 47.4% (n=18) 52.6 (n=20)
>70 years (n=72) 4.2% (n=3) 55.6% (n=40) 40.3% (n=29)
Family history of glaucoma Yes (n=91) 3.3% (n=3) 51.6% (n=47) 45.1% (n=41) χ2 (2,128)=2.61,
p=0.271No (n=37) 8.1% (n=3) 59.5% (n=22) 32.4% (n=12)
Living status Live alone (n=31) 0% (n=0) 45.1% (n=14) 54.8% (n=17) χ2 (2,128)=4.28,
p=0.118Live with family (n=97) 5.2% (n=5) 56.7% (n=55) 37.1% (n=36)
Employment status Working (n=24) 4.2% (n=1) 46.8% (n=11) 50% (n=12) χ2 (2,128)=0.90,
p=0.637Not working (n=104) 4.8% (n=5) 55.8% (n=58) 39.4% (n=41)
Taking other chronic
medication
Yes (n=112)
No (n=16)
3.6% (n=4)
12.5% (n=2)
53.6% (n=60)
56.3% (n=9)
42.9% (n=48)
31.3% (n=5)
χ2 (2,128)=2.86,
p=0.240
Changes in medication 0 changes (n=55)
1 change (n=46)
2 changes (n=27)
3.6% (n=2)
6.5% (n=3)
3.7% (n=1)
54.5% (n=30)
50% (n=23)
59.2% (n=16)
41.8% (n=23)
43.5% (n=20)
37.0% (n=10)
χ2 (2,128)=0.97
p=0.915
Note: *Represents statistically signiﬁcant results.
Dovepress McClelland et al
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Of those found to have increased adherence over the
previous 6 months, reasons included better instillation
techniques, simpler medication regimes, and greater
understanding of the disease. Reasons for decreased adher-
ence were a result of drop insertion difﬁculties and an
increase in drop frequency. Participants reported that they
are often hesitant to ask for help within a busy clinic
environment, particularly if they have been using drops
for long term and feel embarrassed or unwilling to admit
that they require help with something they should be adept
at. When asked if they had ever asked for help with drop
instillation, 85.2% said no, and yet comments such as
Table 3 Reasons for changes in adherence behavior over the previous 6 months
Used medication “more” regularly in last 6 months Used medication “less” regularly in last 6
months
Better at instillation of drops Difﬁculties with drop insertion
More established routine Worsening memory
More practice at putting in drops Do not know what drops are supposed to do
Increased trust in medication Not as worried about eyes as used to be
Better drops and an easier regime More complacent
Disease worsening Too many other worries lately
Better knowledge/understanding of disease – did not know what drops were for
previously
Recent increase in medication – miss morning drop
Table 4 Knowledge of disease perception and adherence
Knowledge of glaucoma MGL Adherence Score
0-1 (low adherence)
n (%)
2-3 (moderate adherence)
n (%)
4 (high adherence)
n (%)
Total
n (%)
A lot 0 (0) 5 (3.9) 4 (3.1) 9 (7.0)
Fair amount 3 (2.3) 26 (20.3) 23 (18.0) 52 (40.6)
Very little 2 (1.6) 33 (25.8) 20 (15.6) 55 (43.0)
None 1 (0.78) 5 (3.9) 6 (4.7) 12 (9.4)
Total 6 (4.7) 69 (53.9) 53 (41.4) 128 (100)
Table 5 Participants’ perception of whether they were “happy” with their treatment
Happy with treatment MGL Adherence score
0-1 (low adherence)
n (%)
2-3 (moderate adherence)
n (%)
4 (high adherence)
n (%)
Total
n (%)
Yes 2 (1.6) 45 (35.2) 38 (29.7) 85 (66.4)
Mostly 4 (3.1) 19 (14.8) 15 (11.7) 38 (29.7)
No 0 (0) 5 (3.9) 0 (0) 5 (3.9)
Total 6 (4.7) 69 (53.9) 53 (41.4) 128 (100)
Table 6 Participants’ perception of whether their glaucoma medication regime was difﬁcult to follow
Was the regime hard to follow? MGL Adherence score
0-1 (low adherence)
n (%)
2-3 (moderate adherence)
n (%)
4 (high adherence)
n (%)
Total
n (%)
Yes/sometimes 3 (2.3) 14 (10.9) 5 (3.9) 22 (17.2)
No 3 (2.3) 55 (43.0) 48 (37.5) 106 (82.8)
Total 6 (4.7) 69 (53.9) 53 (41.4) 128 (100)
McClelland et al Dovepress
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“always put in a couple of times because of poor aim” and
“trouble with aim” show a need for intervention.
Assistance could be a productive addition to clinics, with
patients given the opportunity to ask questions and receive
help for difﬁculties with topical medication.
The present study revealed that there was a larger
percentage of participants with the least knowledge of
“how their drops worked” and the least knowledge of
“what would happen if glaucoma was not treated”, in the
'low adherence' group, however this did not reach statis-
tical signiﬁcance. This is consistent with previous pub-
lished literature,23 which reported that doctor–patient
relationships are one of the most important factors for
adherence to topical medication. Friedmann et al23
reported that understanding how glaucoma affected vision
increased adherence and not knowing how drops worked
decreased adherence. Of the 57 participants (44.5%) that
could articulate what happens if POAG is not treated, only
one person mentioned that the disease was asymptomatic.
This aspect is important when addressing adherence, par-
ticularly in the group of “intentional non-compliers” who
responded with comments including: “Feel like eyes need
a rest from drops” and “Do not bother with morning dose”,
highlighting a lack of knowledge of the consequences of
non-adherence.
Another notable ﬁnding was when asked about whether
they “think their eye drops are working”; almost half
(46.1%) of the participants “were not sure”. This suggests
that patients are using drops without any knowledge of
whether they are effectively controlling glaucoma progres-
sion. Feedback during appointments, such as a written
record of their IOP or results of visual ﬁeld tests, could
be a straightforward yet beneﬁcial way of encouraging
adherence, demonstrating effectiveness of topical medica-
tion. Comments given regarding glaucoma knowledge
such as “Would be nice to know what’s happening”,
“More information would help me manage my condition”
demonstrates a desire for further communication regarding
the disease. However, over half of the participants (54.7%)
also answered “no” to wanting more knowledge, with a
large proportion remarking they “know enough” or they
“trust the doctor”. One participant with excellent adher-
ence and good knowledge of glaucoma stated at the end of
the questionnaire “I do not think I have glaucoma though,
but I use the drops because that’s what the doctor
tells me”.
In the present study, those participants who found their
drop regime “hard to follow” had signiﬁcantly lower
adherence, and the group with “no difﬁculties” demon-
strated statistically signiﬁcant higher adherence. Previous
research has reported higher adherence rates with a sim-
pler dosing regime and that a single daily dose results in
improved adherence.19,35,35 However, although in the pre-
sent study there were a greater proportion of participants
using one drop daily in the adherent group, no signiﬁcant
associations were noted between adherence and drop fre-
quency. This may have been the result of small numbers
recruited in these groups.
Surprisingly, there was a signiﬁcantly larger proportion
of participants who had help with drops at home in the the
‘low adherence’ group. A possible reason for this non-
adherence may be a reliance on others to administer drops
and consequently involving a third party for whom the
importance of the medication may be eclipsed by other
priorities.
The comments section of the questionnaire allowed
participants to discuss any aspect of the clinic, their treat-
ment, and glaucoma. Although some aspects of the dis-
cussion were outside the control of their glaucoma
management (eg, parking), there were some insightful
discussions. One younger participant suggested,
“Counseling should be available for newly diagnosed
patients, especially if they are younger”. This is a percep-
tive comment as there is evidence to show that adherence
with glaucoma treatment is lower in the ﬁrst year of
diagnosis35 and counseling to help with the initial distress
of diagnosis may help patients persevere with their treat-
ment. Adherence has also been shown to be lower in the
younger age groups, often due to a busy lifestyle and work
commitments.14 The present study found that 77.8% of the
youngest age group were within the ‘low/moderate adher-
ence’. This reinforces the need to educate patients on
controlling glaucoma at a young age and soon after initial
diagnosis, hopefully preventing progression to visual
impairment.
Addressing non-adherence requires a multifaceted
approach, dependent on the patients’ needs, attitudes, and
lifestyle. A Cochrane review on interventions to improve
adherence to topical hypotensive therapy35 reported that
individualized patient education and care resulted in
improvements in adherence. Strategies to address adher-
ence depend on the reasons behind individual non-adher-
ence. The most common reason for non-adherence,
“forgetting”, may beneﬁt from education on the beneﬁts of
reminder techniques and establishing strategies to coordi-
nate drop use with daily events. Adherence can also be
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improved by using the simplest treatment regime available.
The use of once-daily dosing or ﬁxed combination drugs are
advised for those who require changes to their medication
regime. Despite conﬂicting comments on the necessity of
glaucoma knowledge by participants in this study, provi-
sions should be made available to those who need it. When
participants were asked whether they would like more
knowledge about glaucoma and its treatment, 45.3% replied
that they would. Several patients mentioned that they would
like more knowledge, if not for themselves, for their chil-
dren so they could advise them about future testing. Many
also asked about the possibility of genetic testing for family
members. This education, for it to be individualized, needs
to be in a form other than patient leaﬂets. Lacey et al27
found that most patients were dissatisﬁed with this type of
education and prefer alternative formats.
Conclusion
Identifying non-adherent patients and addressing their rea-
sons for not using topical medication consistently are
essential at an early stage to prevent progression. Those
patients who use drops just before clinic appointments but
not consistently in-between appointments may explain
why patients progress when they present with IOP in
their target range. The use of eye drop monitors is expen-
sive, and monitors are only available for certain medica-
tions and therefore are not a viable long-term option. This
study has shown the value of administration of a adher-
ence assessment questionnaire by someone independent of
the eye care team. A simple validated questionnaire that
could be completed by patients on arrival at an outpatient’s
appointment would allow these “personal” factors of non-
adherent to be addressed before a patient leaves the clinic.
This would be beneﬁcial not only for glaucoma patients
but also for other ophthalmic patients on long-term topical
medication.
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